Product hopping in the drug industry — lessons from Albuterol
Wouters, O. J.
, Feldman, W. B. & Tu, S. S.
(2022).
Product hopping in the drug industry — lessons from Albuterol.
New England Journal of Medicine,
387(13), 1153 - 1156.
https://doi.org/10.1056/NEJMp2208613
, Feldman, W. B. & Tu, S. S.
(2022).
Product hopping in the drug industry — lessons from Albuterol.
New England Journal of Medicine,
387(13), 1153 - 1156.
https://doi.org/10.1056/NEJMp2208613
Abstract
Product hops to albuterol inhalers containing hydrofluoroalkane rather than chlorofluorocarbons cost payers and patients billions of dollars. Without patent and regulatory reform, this pattern is likely to be repeated.
